Critical Needs in Advancing <i>Shigella</i> Vaccines for Global Health
Calman A. MacLennan, Kawsar R. Talaat, Robert W. Kaminski, Dani Cohen, Mark S. Riddle, Birgitte Giersing
Abstract
Advancing new O-antigen-based Shigella vaccines is critically dependent on development of an international standard serum and harmonized ELISA, demonstration of field efficacy in young children in low- and middle-income countries, and early engagement with regulators and policy makers.
Topics & Concepts
ShigellaImmunologyGlobal healthLow and middle income countriesShigellosisAntigenMedicinePolitical scienceVirologyEnvironmental healthDeveloping countryBiologyPublic healthEconomic growthSalmonellaBacteriaNursingEconomicsGeneticsEscherichia coli research studiesViral gastroenteritis research and epidemiologyVibrio bacteria research studies